Key Findings:  In subjects with chronic prostatitis/chronic pelvic pain treatment with Palmitoylethanolamide plus Alpha-lipoic acid significantly reduced NIH-CPSI score.
Type of Study:  Clinical Trial
Study Sample Size:  44
Study Result:  Positive
Study Location(s):  Italy
Year of Pub:  2017
Cannabinoids Studied:  Palmitoylethanolamide (PEA)
Phytocannabinoid Source:  Unspecified
DOSING DETAILS   
Study Dosing Objective:  Effective Dose, Safety Profile
Established Protocol:  Effective dose
Route of Administration:  Oral (Ingestion)
Dosing Regimen:  Palmitoylethanolamide (300 mg) Alpha-lipoic acid (300 mg)
Treatment Duration:  12 weeks
Clinical Relevance:  Palmitoylethanolamide (PEA) and Alpha-lipoic acid (ALA) shows promising efficacy over Serenoa Repens in patients with CP/CPPS.